COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Targeted PARP or MEK/ERK Inhibition in Patients With Pancreatic Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04005690
Recruitment Status : Recruiting
First Posted : July 2, 2019
Last Update Posted : May 12, 2020
National Cancer Institute (NCI)
Oregon Health and Science University
Information provided by (Responsible Party):
Charles D Lopez, OHSU Knight Cancer Institute

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : June 1, 2020
Estimated Study Completion Date : February 1, 2025